Hui Lyu
Impact in
- Cancer Research top 10%
- Cancer-related molecular mechanisms research
- MicroRNA in disease regulation
- Oncology top 5%
- HER2/EGFR in Cancer Research
- Peptidase Inhibition and Analysis
Papers in
-
- Histone Deacetylase Inhibitors Research 5
- RNA Interference and Gene Delivery 4
- Protein Degradation and Inhibitors 3
- Glycosylation and Glycoproteins Research 3
- Cell death mechanisms and regulation 3
- PI3K/AKT/mTOR signaling in cancer 3
- Oncology 17
- HER2/EGFR in Cancer Research 13
- Co-authors
- Bolin Liu (25 shared papers)Jingcao Huang (11 shared papers)Jian Ma (2 shared papers)Zhimin He (8 shared papers)Jianxiang Wang (3 shared papers)Shuiliang Wang (4 shared papers)Shuang Liu (1 shared paper)Xuefei Shi (1 shared paper)
- Journals
- Cancer Research (4 papers)Biological Procedures Online (3 papers)Cancer Letters (3 papers)Journal of Cellular Biochemistry (2 papers)Molecular Cancer (2 papers)
- Partner nations
- ChinaUnited StatesSouth Korea
In The Last Decade
Hui Lyu
33 papers receiving 991 citations
Peers
Comparison fields: 5 of 84
- Cancer Research 282
- Oncology 469
- Radiology, Nuclear Medicine and Imaging 223
- Molecular Biology 641
- Genetics 43
Countries citing papers authored by Hui Lyu
This map shows the geographic impact of Hui Lyu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hui Lyu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hui Lyu more than expected).
Fields of papers citing papers by Hui Lyu
This network shows the impact of papers produced by Hui Lyu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hui Lyu. The network helps show where Hui Lyu may publish in the future.
Co-authors
The 25 scholars most cited alongside Hui Lyu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 33 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2014 | 143 | |
| 2 | 2016 | 100 | |
| 3 | 2018 | 91 | |
| 4 | MicroRNA regulation and therapeutic targeting of survivin in cancer. | 2015 | 75 |
| 5 | 2022 | 72 | |
| 6 | 2021 | 67 | |
| 7 | 2013 | 54 | |
| 8 | 2019 | 48 | |
| 9 | 2018 | 44 | |
| 10 | 2013 | 42 | |
| 11 | 2014 | 37 | |
| 12 | 2018 | 31 | |
| 13 | 2015 | 28 | |
| 14 | 2013 | 25 | |
| 15 | 2015 | 22 | |
| 16 | 2018 | 15 | |
| 17 | 2021 | 14 | |
| 18 | 2018 | 12 | |
| 19 | 2023 | 11 | |
| 20 | Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells. | 2015 | 10 |
About Hui Lyu
Hui Lyu is a scholar working on Molecular Biology, Oncology, Radiology, Nuclear Medicine and Imaging, Cancer Research and Hematology, having authored 33 papers that have together received 998 indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (13 papers), Monoclonal and Polyclonal Antibodies Research (9 papers), Histone Deacetylase Inhibitors Research (5 papers), RNA Interference and Gene Delivery (4 papers), Protein Degradation and Inhibitors (3 papers), Glycosylation and Glycoproteins Research (3 papers), Cell death mechanisms and regulation (3 papers) and PI3K/AKT/mTOR signaling in cancer (3 papers). The work is most often cited by research in Cancer Research (282 citations), Oncology (469 citations), Radiology, Nuclear Medicine and Imaging (223 citations), Molecular Biology (641 citations) and Genetics (43 citations). Hui Lyu has collaborated with scholars based in China, United States and South Korea. Frequent co-authors include Bolin Liu, Jingcao Huang, Jian Ma, Zhimin He, Jianxiang Wang, Shuiliang Wang, Shuang Liu, Xuefei Shi, Hongbing Liu and Ying Wu. Their work appears in journals such as Cancer Research, Biological Procedures Online, Cancer Letters, Journal of Cellular Biochemistry and Molecular Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.